These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 28494491)

  • 21. Intravitreal anti-VEGF drug delivery systems for age-related macular degeneration.
    Luaces-Rodríguez A; Mondelo-García C; Zarra-Ferro I; González-Barcia M; Aguiar P; Fernández-Ferreiro A; Otero-Espinar FJ
    Int J Pharm; 2020 Jan; 573():118767. PubMed ID: 31669558
    [TBL] [Abstract][Full Text] [Related]  

  • 22. EFFICACY OF ADJUVANT TOPICAL DORZOLAMIDE-TIMOLOL IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY.
    Lee JH; Lee SC; Byeon SH; Koh HJ; Kim SS; Lee CS
    Retina; 2019 Oct; 39(10):1953-1958. PubMed ID: 30161096
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age-related macular degeneration.
    Aslankurt M; Aslan L; Aksoy A; Erden B; Cekiç O
    Eur J Ophthalmol; 2013; 23(4):553-7. PubMed ID: 23516253
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CHANGES IN PLASMA VASCULAR ENDOTHELIAL GROWTH FACTOR LEVEL AFTER INTRAVITREAL INJECTION OF BEVACIZUMAB, AFLIBERCEPT, OR RANIBIZUMAB FOR DIABETIC MACULAR EDEMA.
    Hirano T; Toriyama Y; Iesato Y; Imai A; Murata T
    Retina; 2018 Sep; 38(9):1801-1808. PubMed ID: 29280940
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment.
    Giacomelli G; Finocchio L; Biagini I; Sodi A; Murro V; Introini U; Varano M; Bandello F; Menchini U
    Ophthalmologica; 2017; 238(1-2):44-51. PubMed ID: 28641290
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisation.
    Gasperini JL; Fawzi AA; Khondkaryan A; Lam L; Chong LP; Eliott D; Walsh AC; Hwang J; Sadda SR
    Br J Ophthalmol; 2012 Jan; 96(1):14-20. PubMed ID: 21791509
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
    Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
    Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Wet form age-related macular degeneration two years treatment results using anti VEGF drugs].
    Studnička J; Rencová E; Dusová J; Marák J; Burova M; Rozsíval P; Jarkovský J; Kandrnal V
    Cesk Slov Oftalmol; 2013 Aug; 69(3):96-101. PubMed ID: 24437955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal anti-VEGF therapy blocks inflammatory cell infiltration and re-entry into the circulation in retinal angiogenesis.
    Nakao S; Arima M; Ishikawa K; Kohno R; Kawahara S; Miyazaki M; Yoshida S; Enaida H; Hafezi-Moghadam A; Kono T; Ishibashi T
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4323-8. PubMed ID: 22661475
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term treatment with anti-VEGF does not induce cell aging in primary retinal pigment epithelium.
    Schottler J; Randoll N; Lucius R; Caliebe A; Roider J; Klettner A
    Exp Eye Res; 2018 Jun; 171():1-11. PubMed ID: 29522724
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of anti-VEGF therapies on fibrovascular pigment epithelial detachments in age-related macular degeneration.
    Au A; Parikh VS; Singh RP; Ehlers JP; Yuan A; Rachitskaya AV; Sears JE; Srivastava SK; Kaiser PK; Schachat AP; Martin DF; Modi Y
    Br J Ophthalmol; 2017 Jul; 101(7):970-975. PubMed ID: 27913442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of bevacizumab, ranibizumab, and pegaptanib in vitro: efficiency and possible additional pathways.
    Klettner A; Roider J
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4523-7. PubMed ID: 18441313
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection.
    Semeraro F; Morescalchi F; Duse S; Gambicorti E; Cancarini A; Costagliola C
    Curr Drug Metab; 2015; 16(7):572-84. PubMed ID: 26424177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aqueous vascular endothelial growth factor after intravitreal injection of pegaptanib or ranibizumab in patients with age-related macular degeneration.
    Sawada O; Miyake T; Kakinoki M; Sawada T; Kawamura H; Ohji M
    Retina; 2010; 30(7):1034-8. PubMed ID: 20616682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment Patterns for Myopic Choroidal Neovascularization in the United States: Analysis of the IRIS Registry.
    Willis J; Morse L; Vitale S; Parke DW; Rich WL; Lum F; Cantrell RA
    Ophthalmology; 2017 Jul; 124(7):935-943. PubMed ID: 28372860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short term effects of intravitreal anti-vascular endothelial growth factor agents on cornea, anterior chamber, and intraocular pressure.
    Arslan GD; Guven D; Alkan AA; Kacar H; Demir M
    Cutan Ocul Toxicol; 2019 Dec; 38(4):344-348. PubMed ID: 31092017
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.